{"type":"trials","record":{"id":42266,"source_id":"clinicaltrials-gov","external_id":"NCT05345236","title":"A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)","brief_summary":"This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrollment":366,"countries":["China"],"start_date":"2019-08-19","completion_date":"2022-01-25","last_update_date":"2022-04-25","source_url":"https://clinicaltrials.gov/study/NCT05345236","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Eylea®","organization":"Qilu Pharmaceutical Co., Ltd.","interventions":["Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12","Proportion of subjects who gained at least 5,10 and 15 lettersbaseline to week 12,week 24 and week 52 — Baseline (Day 0…","Change From Baseline in CRT(central retina thickness) by visit — Baseline (Day 0), week 4, week 8, Week 12, Week 24, We…","BCVA Change From Baseline by visit — Baseline (Day 0), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Wee…","Change from baseline in CNV area from baseline to week 12, week 24 and week 52 — Baseline (Day 0), Week 12, Week 24, We…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05345236","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-08-19 to 2022-01-25","comparator":"Eylea®","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.943Z","intervention":["Aflibercept"],"participants":366,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12","Proportion of subjects who gained at least 5,10 and 15 lettersbaseline to week 12,week 24 and week 52 — Baseline (Day 0…","Change From Baseline in CRT(central retina thickness) by visit — Baseline (Day 0), week 4, week 8, Week 12, Week 24, We…","BCVA Change From Baseline by visit — Baseline (Day 0), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Wee…","Change from baseline in CNV area from baseline to week 12, week 24 and week 52 — Baseline (Day 0), Week 12, Week 24, We…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42266","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}